China’s film market is the second-largest in the world by box office revenue, generating roughly $7.4 billion in 2023 and recovering steadily toward its pre-pandemic peak. For foreign studios, distributors, and production companies, that market is simultaneously one of the most lucrative and most tightly controlled in the world. China’s film quota system limits how many foreign films can screen in theaters each year, and navigating it requires either winning a coveted import slot or structuring a formal co-production with a licensed Chinese partner — each path with its own regulatory playbook.
How China’s Film Import Quota Works
China caps the number of foreign films that can receive wide theatrical release to approximately 34 revenue-sharing imports per year, plus an additional quota of flat-fee imports managed at the discretion of the National Radio and Television Administration (NRTA). The 34 revenue-sharing slots are the ones foreign studios compete most aggressively to secure, as they entitle the foreign rights holder to roughly 25% of box office gross — significantly below the 40-50% standard in most other major markets.
NRTA, which absorbed the former SAPPRFT in 2018, reviews all foreign films seeking Chinese theatrical release. The review is substantive: content is scrutinized for political sensitivity, portrayals of Chinese institutions and history, cultural values, and what regulators call “social effect.” Films depicting Taiwan or Tibet as independent, portraying Chinese officials negatively, including LGBTQ+ storylines, or contradicting China’s official historical narrative are routinely denied. There is no effective appeals mechanism for foreign applicants.
Import slots are allocated in practice through China Film Group Corporation (CFGC), a state-owned enterprise that holds a monopoly on foreign film imports. Studios negotiate Chinese release through CFGC, not directly with NRTA, creating a commercial intermediary layer with its own political sensitivities and scheduling priorities.
Even films that secure an import slot face domestic “protection periods” — stretches around Lunar New Year, National Day Golden Week, and summer holidays when only domestic films are permitted to screen. Foreign films are effectively locked out of the highest-grossing windows of the year.
The Co-Production Route: Bypassing the Quota
Films classified as Sino-foreign co-productions are treated as domestic productions under Chinese law. They are not subject to the 34-slot import quota, they qualify for the standard 43% box office revenue share, and they can release during protection periods. The governing framework is the Regulations on Sino-Foreign Cooperative Film Production, administered by NRTA.
To qualify as a genuine co-production rather than a “disguised import,” the project must meet several substantive criteria:
- Chinese investment: The Chinese partner must contribute meaningful production financing. Token financial participation will draw NRTA scrutiny.
- Chinese creative involvement: The film must include Chinese cast in significant roles, Chinese creative staff (directors, writers, or cinematographers), and Chinese-set scenes or storylines. Retrofitting a short Shanghai sequence after development does not satisfy regulators.
- Registered co-producer: The Chinese partner must hold an NRTA production license (《摄制电影许可证》). Not every company with “film” in its name qualifies.
- Script approval before production: The script must receive NRTA approval before principal photography begins. Changes require re-submission and can delay production by weeks or months.
Key Contract Terms to Negotiate Carefully
IP and Copyright Ownership
Under Chinese copyright law, co-produced works are jointly owned unless the agreement specifies otherwise. Foreign studios typically retain world rights outside Greater China while granting Chinese box office and streaming rights to the co-production entity. Define precisely who owns the negative, who controls international distribution, and what happens to streaming rights by territory. Resolving co-production disputes in Chinese courts is costly and slow — contractual clarity upfront is far cheaper.
Revenue Share and Accounting
Chinese theatrical accounting is opaque. Box office reporting flows through the China Film Administration’s ticketing verification system, but underreporting by theaters has been documented in multiple enforcement cases. Co-production agreements should require quarterly accountings, audit rights, and payments in USD remitted to an offshore account. Repatriating RMB film revenues through SAFE requires documentation of the underlying co-production agreement and can take several months.
Content Changes and Regulatory Risk Allocation
Who bears the cost if NRTA requires re-shoots or scene deletions after initial submission? Chinese partners often push for shared costs. Foreign studios should negotiate that content changes required solely due to NRTA regulatory review are borne by the Chinese co-producer, who is better positioned to anticipate what the regulator will flag.
Streaming Rights
Chinese streaming platforms — iQiyi, Youku (Alibaba), and Tencent Video — increasingly co-finance original content. Agreements should specify platform exclusivity windows, fee structures, sub-licensing rights, and whether the film can appear on foreign streaming services during the Chinese platform exclusivity period. This is an area where China’s digital commerce landscape evolves rapidly and contract terms can become outdated quickly.
Practical Steps for Foreign Studios
Identify a qualified Chinese co-producer early. Your partner must hold an NRTA production license and, ideally, a track record of domestic releases. CFGC, Bona Film Group, Huanxi Media, and CMC Pictures are among the larger entities with NRTA relationships. Apply the same due diligence principles you would to any Chinese business partner — verify business registration, check for administrative penalties, and speak to prior international co-production partners.
Build regulatory runway. NRTA review for the preliminary “intention letter” stage takes 30-60 days and may involve multiple rounds of script feedback. Build at least three to four months of pre-production time into your schedule before filming begins.
Plan for a dual-version release. Many successful co-productions release different versions in China and international markets. The Chinese version may include extended scenes featuring Chinese cast or adjusted historical framing. The foreign party typically retains control of the international cut; the Chinese co-producer manages the domestic version with NRTA. This should be anticipated contractually, not negotiated in post-production.
The Political Reality: Market Access Fluctuates
China’s film market access has historically tracked the broader diplomatic climate. During periods of US-China trade tension, NRTA approvals for certain national origin content slow or halt. Studios that built China-dependent revenue models without geographic diversification have faced significant exposure when access dried up without warning. Foreign studios should treat China box office as upside, not base-case revenue, and structure co-production deals to remain economically viable even if Chinese theatrical performance falls short.
Understanding China’s broader market entry environment — including how Tier 1, 2, and 3 cities differ in audience demographics and theatrical infrastructure — is essential context for any distribution strategy, since Tier 2 and 3 markets now drive the majority of national box office growth.
For comprehensive reference, the Motion Picture Association’s China market resource page documents current co-production treaty frameworks, and the USTR’s annual National Trade Estimate Report details documented barriers including quota enforcement and approval timelines. Both are essential reading before committing to a Chinese co-production strategy.